Bioabsorbable Stents Market Size, Share, Growth and Forecast (2026 - 2036)

Bioabsorbable Stents Market Analysis and Forecast by Fact.MR

The bioabsorbable stents market, valued at USD 0.49 billion in 2025, is expanding at a 10.2% CAGR to reach USD 1.426 billion by 2036. Bioabsorbable stents are vascular scaffolds designed to provide temporary mechanical support to coronary or peripheral arteries and gradually dissolve over months to years, eliminating the permanent metallic implant associated with conventional drug-eluting stents. Growth reflects improving clinical outcomes from next-generation scaffold designs, expanding coronary artery disease treatment volumes, and growing interventional cardiologist confidence in bioresorbable technology. The USD 0.886 billion incremental opportunity between 2026 and 2036 is concentrated in coronary artery disease applications across Asia, Europe, and North America.

Summary of Bioabsorbable Stents Market

• Market Snapshot
  • Market value in 2025: USD 0.49 billion
  • Projected value in 2026: USD 0.54 billion; forecast to reach USD 1.426 billion by 2036
  • CAGR from 2026 to 2036: 10.2%
  • Incremental opportunity (2026 to 2036): USD 0.886 billion
  • Bioabsorbable polymer-based stents lead material demand with 63.7% share in 2025
  • China and India lead country-level growth, followed by Germany and Brazil
• Demand and Growth Drivers
  • Coronary artery disease prevalence continues to rise globally with aging populations and metabolic risk factors, sustaining percutaneous coronary intervention volumes that create the procedural base for stent implantation.
  • Next-generation bioabsorbable stent designs with thinner struts, improved radial strength, and optimized resorption profiles are addressing the clinical limitations of first-generation products, rebuilding interventional cardiologist confidence.
  • Patient preference for temporary implants that restore natural vessel function after healing is creating a demand-side pull for bioabsorbable alternatives to permanent metallic stents, particularly among younger patients.
  • Regulatory pathways for bioabsorbable stents are maturing in the USA, EU, and Asia, with updated clinical trial requirements providing clearer commercialization timelines for manufacturers.
• Product and Segment View
  • Bioabsorbable polymer-based stents hold 63.7% of material demand, driven by the clinical maturity of poly-L-lactic acid (PLLA) scaffold technology and its established regulatory pathway.
  • Coronary artery diseases account for 71.2% of application share, reflecting the primary clinical indication for bioabsorbable stent implantation in percutaneous coronary intervention.
  • Hospitals hold 66.9% of end-user demand, as catheterization laboratory-based stent implantation procedures are predominantly performed in hospital settings.
  • Key segmentation includes:
    • Material: Bioabsorbable Polymer Based Stents, Bioabsorbable Metallic Stents
    • Absorption Rate: Slow, Fast
    • Application: Coronary Artery Diseases, Peripheral Artery Diseases
    • End User: Hospitals, Cardiac Centers
• Geography and Competitive Outlook
  • North America is a significant revenue region, with the USA contributing USD 0.191 billion in 2025 through advanced interventional cardiology infrastructure and clinical trial activity.
  • East Asia is the fastest-growing region, with China recording the highest country CAGR driven by coronary intervention volume growth and domestic bioabsorbable stent development.
  • Europe maintains strong growth, with Germany leading through clinical research leadership and early adoption of next-generation bioresorbable scaffold designs.
  • Abbott Laboratories leads the competitive field with a 22.5% market share, followed by BIOTRONIK, REVA Medical, and Elixir Medical Corporation.
• Analyst Opinion
  • The bioabsorbable stents market is in a recovery phase following the clinical setbacks of first-generation products. The withdrawal of Abbott's Absorb BVS in 2017 due to late scaffold thrombosis concerns created a temporary adoption pause, but the market is now rebuilding as next-generation designs demonstrate improved safety profiles in clinical trials. Thinner struts, faster resorption timelines, and enhanced radial strength are addressing the specific failure modes identified with earlier products. Fact.MR expects commercial growth to accelerate as pivotal trial results for next-generation platforms are published and regulatory approvals follow. The primary growth driver will be interventional cardiologist willingness to adopt bioabsorbable technology once clinical evidence meets the safety thresholds established by incumbent metallic drug-eluting stents.

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Next-generation design improvement: Thinner strut profiles (below 100 microns), optimized resorption kinetics, and improved radial strength are addressing the scaffold thrombosis and late lumen loss concerns that limited first-generation product adoption.
• Coronary intervention volume growth: Rising percutaneous coronary intervention counts across developing and developed markets expand the procedural base for stent implantation, creating a growing addressable market for bioabsorbable alternatives.
• Younger patient preference: Patients under 50 undergoing coronary intervention increasingly express preference for temporary implants that restore natural vessel function, creating a physician-patient shared decision dynamic that favors bioabsorbable options.

Key Market Constraints

• First-generation safety legacy: Clinical data showing elevated late scaffold thrombosis rates with first-generation bioabsorbable stents continues to influence interventional cardiologist prescribing behavior, requiring substantial next-generation evidence to overcome adoption hesitancy.
• Pricing premium over metallic DES: Bioabsorbable stents carry price premiums of 50% to 100% over established metallic drug-eluting stents, creating payer and institutional procurement resistance in cost-sensitive healthcare systems.
• Limited long-term outcome data: Next-generation bioabsorbable stent designs lack the 5- to 10-year clinical outcome data available for established metallic DES platforms, creating evidence gaps that slow clinical guideline incorporation.

Key Opportunity Areas

• Magnesium-based bioresorbable scaffolds: Next-generation metallic bioabsorbable stents using magnesium alloys offer thinner strut profiles and faster resorption compared to polymer scaffolds, potentially addressing the mechanical limitations that constrained first-generation products.
• Peripheral artery disease expansion: Bioabsorbable stent application in peripheral arteries, particularly below-the-knee interventions, is an emerging indication where temporary scaffolding is clinically attractive due to the mechanical stress environment.
• Combination with drug-coated balloon therapy: Sequential use of drug-coated balloons followed by bioabsorbable scaffolding is emerging as a treatment strategy that could expand the clinical role of bioresorbable technology.

Segment-wise Analysis of the Bioabsorbable Stents Market

• Bioabsorbable polymer-based stents lead material demand at 63.7%, driven by PLLA scaffold technology maturity and regulatory pathway establishment.
• Coronary artery diseases hold 71.2% of application share, as the primary clinical indication for bioabsorbable stent implantation.
• Slow-absorption stents account for 58.4% of absorption rate demand, reflecting clinical preference for gradual scaffold resorption that maintains support during vessel healing.

Which material dominates the Bioabsorbable Stents Market?

Bioabsorbable polymer-based stents hold a 63.7% share of material demand in 2025, the dominant material category. The share reflects the clinical and commercial maturity of poly-L-lactic acid (PLLA) scaffolds, which have accumulated the most extensive clinical trial data and regulatory approval history among bioabsorbable stent materials. PLLA stents provide predictable resorption timelines and established drug-elution compatibility, making them the default material choice for manufacturers with active bioabsorbable stent programs.

Bioabsorbable metallic stents, primarily magnesium-based scaffolds, represent the emerging material segment. Magnesium scaffolds offer thinner strut profiles and mechanical properties closer to metallic DES, potentially addressing the radial strength and deliverability limitations of polymer-based designs. BIOTRONIK's magnesium-based Magmaris scaffold is the most clinically advanced metallic bioabsorbable product, with expanding clinical data supporting its safety profile.

Which application dominates the Bioabsorbable Stents Market?

Coronary artery diseases account for 71.2% of application demand in 2025, the dominant application category. The share reflects the primary clinical indication for bioabsorbable stent implantation in percutaneous coronary intervention, where the restoration of natural vessel vasomotion after scaffold resorption is the core clinical value proposition. De novo coronary lesions in younger patients represent the target population where the long-term benefit of avoiding permanent metallic implants is most clinically compelling.

Peripheral artery diseases represent the emerging application, where bioabsorbable scaffolding is gaining interest for below-the-knee interventions and other peripheral vascular indications. The mechanical stress environment in peripheral arteries creates both opportunities and challenges for bioabsorbable designs, as scaffold fatigue resistance must accommodate the flexion and compression forces present in limb vasculature.

Which absorption rate dominates the Bioabsorbable Stents Market?

Slow-absorption stents hold 58.4% of absorption rate demand in 2025, reflecting clinical preference for scaffolds that maintain radial support during the critical vessel healing period of 6 to 12 months before initiating gradual resorption. Slow-absorption designs align with the biological timeline of neointimal tissue formation, providing mechanical support until the vessel wall has sufficient structural integrity to maintain patency independently.

Fast-absorption stents are gaining clinical interest for specific indications where shorter scaffolding duration is desirable, such as small-vessel coronary lesions and certain peripheral applications. The fast-absorption segment is smaller but growing as manufacturers develop materials with accelerated but controlled degradation profiles.

Which Product Trend is Shaping the Next Phase of Growth in the Bioabsorbable Stents Market?

Next-generation thin-strut bioabsorbable scaffold designs are shaping the comeback of this technology category after the clinical setbacks of first-generation products. The primary technical advancement is strut thickness reduction from the 150+ micron profiles of first-generation PLLA scaffolds to sub-100-micron designs using both improved polymer processing and metallic bioabsorbable materials. Thinner struts reduce flow disturbance, lower scaffold thrombosis risk, and improve deliverability through tortuous coronary anatomy. Clinical trial data from next-generation thin-strut platforms, including magnesium-based Magmaris and new PLLA designs from multiple manufacturers, are demonstrating safety profiles approaching metallic DES benchmarks.

The commercial trajectory of bioabsorbable stents depends on the publication of pivotal trial results and subsequent regulatory approvals expected between 2025 and 2028. Interventional cardiologist adoption will be evidence-driven, requiring non-inferiority to metallic DES on target lesion failure endpoints at 1-year and 3-year follow-up. Fact.MR projects that regulatory approvals of next-generation designs will trigger a re-adoption cycle that returns bioabsorbable stent utilization to growth trajectories by 2028, with the market reaching its full potential as longer-term safety data accumulates through 2036.

Regional Outlook Across Key Markets

• North America is a significant market, with the USA contributing USD 0.191 billion in 2025 through clinical trial activity and early adoption in specialized cardiac centers.
• East Asia is the fastest-growing region, with China recording the highest country CAGR driven by coronary intervention growth and domestic bioresorbable stent development.
• Europe maintains strong growth, with Germany leading through interventional cardiology research and clinical trial site density.
• South Asia is an emerging corridor, with India recording strong CAGR driven by coronary disease burden and cost-sensitive demand for alternative stent technologies.

CAGR Table

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

China:Domestic development and coronary intervention growth

China records the highest country-level CAGR in the bioabsorbable stents market, driven by rapid coronary intervention volume growth, domestic bioabsorbable stent development by companies including MicroPort Scientific, and government policy supporting medical device self-sufficiency. Chinese NMPA has established a regulatory pathway for bioabsorbable vascular scaffolds, and multiple domestic manufacturers have products in clinical trials targeting the Chinese coronary intervention market. The cost-sensitivity of the Chinese healthcare system creates interest in bioabsorbable alternatives that may reduce long-term follow-up and retreatment costs.

• Growth anchor: Domestic bioabsorbable stent development and coronary intervention volume growth create a dual supply-demand growth dynamic.

USA: Clinical trial activity and specialized adoption

The USA contributes USD 0.191 billion in 2025, with growth driven by clinical trial activity for next-generation bioabsorbable platforms, early adoption in specialized cardiac centers, and FDA regulatory pathway development. The interventional cardiology community in the USA is evidence-driven, and adoption of bioabsorbable stents will accelerate following publication of positive pivotal trial results for next-generation designs. FDA breakthrough device designation for select bioabsorbable stent programs may accelerate regulatory review timelines.

• Growth anchor: Pivotal trial results and potential FDA breakthrough device designations are the primary near-term catalysts for market growth.

Germany: Research leadership and clinical trial infrastructure

Germany leads European bioabsorbable stent growth, supported by its dense network of interventional cardiology research centers and high participation rates in bioabsorbable stent clinical trials. German cardiac centers serve as principal investigation sites for multiple next-generation scaffold studies, creating early physician familiarity with evolving designs. The country's statutory health insurance system provides coverage for approved stent technologies.

• Growth anchor: Clinical trial site density and research leadership create early adopter familiarity with next-generation bioabsorbable scaffold designs.

India: Coronary disease burden and cost-driven adoption

India records strong growth driven by the high burden of coronary artery disease, expanding percutaneous intervention capacity, and interest in bioabsorbable technology as a long-term cost reduction strategy. Indian cardiac device manufacturers are exploring bioabsorbable stent development to serve the price-sensitive domestic market. The large patient population requiring coronary intervention provides a substantial addressable market for bioabsorbable alternatives.

• Growth anchor: High coronary disease burden and price-sensitive market dynamics create interest in bioabsorbable alternatives that reduce long-term follow-up costs.

Competitive Benchmarking and Company Positioning

Bioabsorbable Stents Market Analysis By Company

• Abbott Laboratories leads with 22.5% market share, maintaining its position through continued investment in next-generation bioabsorbable scaffold technology following the Absorb BVS withdrawal, with new platform candidates in clinical development.
• BIOTRONIK competes through its Magmaris magnesium-based bioresorbable scaffold, the most clinically advanced metallic bioabsorbable stent with expanding clinical evidence supporting its safety profile.
• REVA Medical and Elixir Medical Corporation are specialized bioabsorbable stent companies with proprietary polymer technologies targeting differentiated resorption and mechanical performance profiles.

The competitive field is concentrated among a small number of specialized players and large medical device companies with dedicated bioabsorbable stent programs. Abbott's market share reflects its first-mover legacy and continued R&D investment in next-generation polymer scaffolds designed to address the limitations identified with Absorb BVS. The company's global interventional cardiology distribution infrastructure provides a commercial launch advantage once new products receive regulatory approval.

BIOTRONIK differentiates through its magnesium-based approach, which offers fundamentally different mechanical and resorption properties compared to polymer scaffolds. The Magmaris platform's thinner strut profile and metallic mechanical behavior may appeal to interventional cardiologists seeking bioabsorbable technology with handling characteristics closer to conventional metallic stents.

Emerging competition from MicroPort Scientific (China), Arterial Remodelling Technologies (France), and other developers is expanding the pipeline of bioabsorbable stent candidates, increasing the probability of multiple commercially available products by the late 2020s.

Key Companies in the Bioabsorbable Stents Market

Abbott Laboratories, BIOTRONIK, REVA Medical Inc., Elixir Medical Corporation, Arterial Remodelling Technologies S.A., Kyoto Medical Planning Co. Ltd., MicroPort Scientific Corporation, and Arterius Ltd. are the principal companies operating in the global bioabsorbable stents market.

Recent Industry Developments

• BIOTRONIK: Magmaris clinical data publication (2025)
  • BIOTRONIK published extended follow-up clinical data for the Magmaris magnesium-based bioresorbable scaffold in 2025, demonstrating safety and efficacy outcomes that approach metallic drug-eluting stent benchmarks at 3-year follow-up.
• Abbott Laboratories: next-generation bioabsorbable scaffold trial initiation (2025)
  • Abbott initiated a pivotal clinical trial for its next-generation bioabsorbable polymer scaffold in 2025, incorporating thinner strut design and modified resorption kinetics developed to address the limitations identified with the earlier Absorb BVS platform.
• MicroPort Scientific: Chinese bioabsorbable stent regulatory submission (2025)
  • MicroPort Scientific submitted regulatory documentation to NMPA in 2025 for its domestically developed bioabsorbable polymer stent, targeting commercial approval for the Chinese coronary intervention market.
• Elixir Medical: novel polymer scaffold advancement (2026)
  • Elixir Medical advanced its proprietary bioabsorbable polymer scaffold into expanded clinical evaluation in early 2026, with a design featuring sub-80-micron strut thickness and a targeted 12-month resorption timeline.

Leading Companies Shaping the Bioabsorbable Stents Market

• Global Players

  • Abbott Laboratories
  • BIOTRONIK
  • REVA Medical, Inc.
  • Elixir Medical Corporation
  • MicroPort Scientific Corporation

• Regional Players

  • Arterial Remodelling Technologies S.A.
  • Kyoto Medical Planning Co. Ltd.
  • Arterius Ltd.

• Emerging / Start-up Players

  • Amaranth Medical
  • Xenogenics Corporation
  • Meril Life Sciences

Sources and Research References

• Abbott Laboratories Annual Report 2024 and Vascular Division Investor Presentations
• BIOTRONIK Magmaris Clinical Data Publications and Regulatory Filings
• FDA PMA Database and Breakthrough Device Designation Records for Bioabsorbable Stents
• ESC (European Society of Cardiology) Clinical Trial Presentations on Bioresorbable Scaffolds
• ACC (American College of Cardiology) Interventional Cardiology Conference Proceedings
• WHO Global Health Estimates for Cardiovascular Disease Burden

All numerical data in this report is derived from Fact.MR proprietary research. Source references are provided for contextual and directional validation only.

Key Questions This Report Addresses

• What is the projected size of the bioabsorbable stents market by 2036?
• Which material holds the largest share?
• What CAGR is expected from 2026 to 2036?
• Which country is the fastest-growing market?
• Who is the leading company?
• What is the incremental opportunity between 2026 and 2036?
• How are next-generation designs affecting market recovery?
• What role do magnesium-based scaffolds play in the market?

Bioabsorbable Stents Market Definition

The bioabsorbable stents market covers temporary vascular scaffolds made from biodegradable polymers or metals that dissolve after providing mechanical support to treated arteries. These devices are used in percutaneous coronary interventions and peripheral vascular procedures as alternatives to permanent metallic stents, with the goal of restoring natural vessel vasomotion after scaffold resorption.

Bioabsorbable Stents Market Inclusions

• Bioabsorbable polymer-based stents (PLLA, PDLLA, and other biodegradable polymer scaffolds)
• Bioabsorbable metallic stents (magnesium-based and iron-based bioresorbable scaffolds)
• Stents for coronary artery disease and peripheral artery disease applications
• Devices implanted in hospitals and cardiac centers through catheterization laboratory procedures

Bioabsorbable Stents Market Exclusions

• Permanent metallic drug-eluting stents and bare-metal stents
• Coronary artery bypass graft surgical procedures and related consumables
• Drug-coated balloons and other non-stent interventional cardiology devices
• Diagnostic cardiac catheterization equipment and imaging systems

Bioabsorbable Stents Market Research Methodology

• Bottom-up revenue modeling using procedural volume data, average stent selling prices, and implantation rates across 15+ countries
• Primary interviews with interventional cardiologists, hospital catheterization laboratory directors, and medical device procurement managers
• Cross-referencing regulatory approval databases (FDA PMA, CE marking, NMPA) for bioabsorbable stent registrations and clinical trial data
• Validation of segment shares through clinical trial publications, physician survey data, and manufacturer product portfolios
• Forecasting calibrated against coronary intervention volume projections, clinical trial completion timelines, and regulatory approval schedules
• Company-level revenue triangulation using annual reports, SEC filings, and investor presentations from listed medical device companies